Holen Sie sich die Stockscreener-App
67.55
0.22%
0.145
Handel nachbörslich:
67.55
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by GW&K Investment Management LLC - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Lifted by Franklin Resources Inc. - MarketBeat
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
BridgeBio Pharma Insider Sold Shares Worth $5,413,289, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma(BBIO.US) Officer Sells US$5.41 Million in Common Stock - Moomoo
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock - Investing.com
BridgeBio Pharma (BBIO) CEO’s family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Mizuho reiterates Outperform on BridgeBio stock on Russell move By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Uncovering a Potential 51.92% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Operating income of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Return on assets % of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Gross profit of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
ETFs Investing in BridgeBio Pharma, Inc. Stocks - TradingView
BridgeBio Pharma, Inc. Balance Sheet – XETR:2CL - TradingView
BridgeBio Pharma, Inc. Cash Flow – XETR:2CL - TradingView
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
Brazil approves BridgeBio’s acoramidis for heart condition - Investing.com
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
BBIO: Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches - TradingView
BBIO: Attruby's rapid growth and differentiated data drive momentum as multiple rare disease launches near - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio (BBIO) Receives Buy Rating with $104 Target by Canacco - GuruFocus
CCORF Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $104 - Moomoo
Canaccord Genuity Group Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Precision Trading with Bridgebio Pharma Inc. (BBIO) Risk Zones - Stock Traders Daily
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential - DirectorsTalk Interviews
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio gains as muscular dystrophy therapy gets FDA priority review - MSN
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98. - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 - GuruFocus
FDA accepts BridgeBio’s BBP-418 for priority review - The Pharma Letter
BridgeBio (BBIO) Secures FDA Filing Acceptance for BBP-418 - GuruFocus
FDA grants Priority Review to BridgeBio (NASDAQ: BBIO) BBP-418 NDA - Stock Titan
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for B - GuruFocus
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for BBP-418 - GuruFocus
BridgeBio gains FDA review for muscle disorder drug (BBIO) - Seeking Alpha
BridgeBio’s LGMD2I/R9 drug receives FDA priority review By Investing.com - Investing.com Nigeria
BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Status - Quiver Quantitative
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - The Manila Times
BridgeBio’s LGMD2I/R9 drug receives FDA priority review - Investing.com
FDA priority review for first potential LGMD2I/R9 treatment - Stock Titan
BridgeBio Pharma Shares Fall After Raymond James Downgrade - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing - Moomoo
BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades - Stock Titan
BBIO Downgraded by Raymond James -- Rating Changed to Market Per - GuruFocus
BridgeBio Pharma (BBIO) Downgraded by Raymond James Amid Competi - GuruFocus
4.65%
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):